Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217815 | 0.82 | CTRB1 (0.57) | CTRB1LMNASMN1; SMN2SYKCASP1 | |
| SCHEMBL22296765 | 0.76 | CTRB1 (0.50) | CTRB1LMNASMN1; SMN2SYKCASP1 | |
| SCHEMBL25346671 | 0.76 | CTRB1 (0.47) | CTRB1LMNASMN1; SMN2SYKCASP1 | |
| SCHEMBL24383269 | 0.75 | SYK (0.58) | CTRB1LMNASMN1; SMN2SYKCASP1 | |
| SCHEMBL30980753 | 0.75 | CTRB1 (0.54) | CTRB1LMNASMN1; SMN2SYKCASP1 | |
| SCHEMBL30980617 | 0.74 | CTRB1 (0.53) | CTRB1LMNASMN1; SMN2CTSKTACR1 | |
| SCHEMBL24383260 | 0.72 | HTT (0.48) | CTRB1LMNASMN1; SMN2HTT | |
| SCHEMBL22692721 | 0.72 | CTRB1 (0.43) | CTRB1LMNASMN1; SMN2SYKCASP1 | |
| SCHEMBL10187034 | 0.72 | CTRB1 (0.59) | CTRB1LMNASMN1; SMN2SYKCASP1 | |
| SCHEMBL30103372 | 0.71 | CTRB1 (0.56) | CTRB1LMNASMN1; SMN2SYKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | CTRB1 3034/4885LMNA 2495/4885SMN1; SMN2 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.